Halozyme to Present at Upcoming Investor Conferences
Halozyme Therapeutics (NASDAQ: HALO) has announced its executive leadership team's upcoming presentations at two major investor conferences on December 4, 2024. Chief Financial Officer Nicole LaBrosse will present at the Piper Sandler 36th Annual Healthcare Conference in New York at 10:30am PT, while President and CEO Helen Torley will speak at the 7th Annual Evercore ISI HealthCONx Conference in Miami at 9:30am PT.
Both events will feature fireside chats and one-on-one meetings. Live audio webcasts will be available on the company's Investor Relations website, with replays accessible for 90 days after the conferences.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato che il suo team di leadership esecutiva parteciperà a due importanti conferenze per investitori il 4 dicembre 2024. Il Direttore Finanziario Nicole LaBrosse presenterà alla 36ª Conferenza Annuale sulla Salute di Piper Sandler a New York alle 10:30 PT, mentre la Presidente e CEO Helen Torley parlerà alla 7ª Conferenza Annuale Evercore ISI HealthCONx a Miami alle 9:30 PT.
Entrambi gli eventi includeranno conversazioni informali e incontri individuali. Saranno disponibili delle registrazioni audio in diretta sul sito web delle Relazioni con gli Investitori dell'azienda, con la possibilità di riascoltarle per 90 giorni dopo le conferenze.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado que su equipo de liderazgo ejecutivo participará en dos importantes conferencias de inversores el 4 de diciembre de 2024. La Directora Financiera Nicole LaBrosse presentará en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York a las 10:30 PT, mientras que la Presidenta y CEO Helen Torley hablará en la 7ª Conferencia Anual Evercore ISI HealthCONx en Miami a las 9:30 PT.
Ambos eventos incluirán charlas informales y reuniones uno a uno. Se ofrecerán webcasts de audio en vivo en el sitio web de Relaciones con Inversores de la empresa, con repeticiones accesibles durante 90 días después de las conferencias.
Halozyme Therapeutics (NASDAQ: HALO)는 2024년 12월 4일에 두 개의 주요 투자자 회의에서 경영진 팀의 발표를 진행한다고 발표했습니다. 최고 재무 책임자 니콜 라브로스는 뉴욕의 파이퍼 샌들러 제36회 연례 헬스케어 회의에서 태평양 표준시 기준 오전 10시 30분에 발표할 예정이며, 회장 겸 CEO 헬렌 토를리는 마이애미에서 열리는 제7회 에버코어 ISI 헬스컨넥스 회의에서 오전 9시 30분에 연설할 예정입니다.
두 행사 모두 대화형 토론 및 일대일 미팅이 포함됩니다. 회사의 투자자 관계 웹사이트에서 라이브 오디오 웹캐스트를 이용할 수 있으며, 회의 종료 후 90일 동안 다시 들을 수 있습니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé que son équipe de direction exécutive participera à deux grandes conférences pour investisseurs le 4 décembre 2024. La Directrice Financière Nicole LaBrosse présentera à la 36ème Conférence Annuelle sur la Santé de Piper Sandler à New York à 10h30 PT, tandis que la Présidente et CEO Helen Torley parlera à la 7ème Conférence Annuelle Evercore ISI HealthCONx à Miami à 9h30 PT.
Les deux événements incluront des discussions informelles et des réunions individuelles. Des webcasts audio en direct seront disponibles sur le site des Relations Investisseurs de l'entreprise, avec des rediffusions accessibles pendant 90 jours après les conférences.
Halozyme Therapeutics (NASDAQ: HALO) hat angekündigt, dass das Führungsteam an zwei wichtigen Investorenkonferenzen am 4. Dezember 2024 teilnehmen wird. Die Finanzvorständin Nicole LaBrosse wird auf der 36. jährlichen Healthcare-Konferenz von Piper Sandler in New York um 10:30 Uhr PT präsentieren, während Präsidentin und CEO Helen Torley auf der 7. jährlichen Evercore ISI HealthCONx-Konferenz in Miami um 9:30 Uhr PT sprechen wird.
Beide Veranstaltungen werden informelle Gespräche und persönliche Meetings umfassen. Live-Audio-Webcasts werden auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit Wiederholungen, die 90 Tage nach den Konferenzen zugänglich sind.
- None.
- None.
Details on the presentations are as follows:
Event: | Piper Sandler 36th Annual Healthcare Conference | |||
Presenter: | Nicole LaBrosse, Chief Financial Officer | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Wednesday, December 4, 2024 | |||
Presentation Time: | 10:30am PT / 1:30pm ET | |||
Location: | ||||
Event: | 7th Annual Evercore ISI HealthCONx Conference | |||
Presenter: | Helen Torley, President and Chief Executive Officer | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Wednesday, December 4, 2024 | |||
Presentation Time: | 9:30am PT / 12:30pm ET | |||
Location: | ||||
A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-302317305.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme (HALO) presenting at the Piper Sandler Healthcare Conference in 2024?
Who will represent Halozyme (HALO) at the Evercore ISI HealthCONx Conference 2024?
How long will Halozyme's (HALO) conference presentation webcasts be available?
What format will Halozyme's (HALO) presentations take at the December 2024 conferences?
